A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
A phase 1/2 trial of Mosunetuzumab, Polatuzumab vedotin, Tocilizumab in hodgkin lymphoma and non-hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT03671018 by Hoffmann-La Roche, with 422 participants planned, started 2018-09-25 and due to reach its primary completion in 2024-01-30. Interventions recorded: Mosunetuzumab (IV), Mosunetuzumab (SC), Polatuzumab vedotin, Tocilizumab, Rituximab. Conditions listed: B-cell Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
Shares Mosunetuzumab, Tocilizumab, Roche / Genentech, Non-Hodgkin lymphoma (all types).
- TrialA Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokineti
Shares Mosunetuzumab, Tocilizumab, Roche / Genentech.
- TrialA Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomi
Shares Mosunetuzumab, Rituximab, Roche / Genentech.
- TrialA Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat
Shares Tocilizumab, Roche / Genentech, Non-Hodgkin lymphoma (all types).
- TrialAn Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Shares Polatuzumab vedotin, Tocilizumab, Hodgkin lymphoma.
- TrialA Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Shares Mosunetuzumab, Rituximab, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TrialSUNMO
Shares Mosunetuzumab, Polatuzumab vedotin.
- TrialA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu
Shares Rituximab, Roche / Genentech, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.